ArticleJournal of orthopaedic translation2021
Losartan protects against osteoarthritis by repressing the TGF-β1 signaling pathway
Article in Journal of orthopaedic translation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 30 citations in OpenAlex.
- Methylation regulatory networks in osteoarthritis: mechanisms and targeted therapies.Journal of translational medicine · 2026Review
- Article
- Eosinophilic Esophagitis: Mechanisms of Disease and Approach to Treatment.Current allergy and asthma reports · 2026Review
- Computational translation of mouse models of osteoarthritis predicts human disease.Osteoarthritis and cartilage · 2026Article
- Artemisinin exerts anti-inflammatory effects in osteoarthritis through the inhibition of TGF-β1 signaling.Frontiers in immunology · 2026Article
- CDK5 regulates PPARγ/NF-κB signaling to exacerbate obesity-related osteoarthritis via modulating macrophage polarization and chondrocyte apoptosis.Cellular & molecular biology letters · 2025Article
- Unlocking Novel Therapeutic Potential of Angiotensin II Receptor Blockers.International journal of molecular sciences · 2025Review
- Inflammatory mechanisms underlying metabolic syndrome-associated and potential treatments.Osteoarthritis and cartilage open · 2025Article
- LRP1 Mediates Endocytosis Activity and Is a Potential Therapeutic Target in Osteoarthritis.Orthopaedic surgery · 2025Review
- Targeting Chondrocyte Hypertrophy as Strategies for the Treatment of Osteoarthritis.Bioengineering (Basel, Switzerland) · 2025Review
- The axis of tumor-associated macrophages, extracellular matrix proteins, and cancer-associated fibroblasts in oncogenesis.Cancer cell international · 2024Review
- Enhancing Cartilage Repair: Surgical Approaches, Orthobiologics, and the Promise of Exosomes.Life (Basel, Switzerland) · 2024Review
- Hsa_circular RNA_0045474 Facilitates Osteoarthritis Via Modulating microRNA-485-3p and Augmenting Transcription Factor 4.Molecular biotechnology · 2024Article
- Knee osteoarthritis: A review of animal models and intervention of traditional Chinese medicine.Animal models and experimental medicine · 2024Review
- Revealing a Natural Model of Pre-Osteoarthritis of the Hip Through Study of Femoroacetabular Impingement.HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2023Article
- Osteoarthritis: Role of Peroxisome Proliferator-Activated Receptors.International journal of molecular sciences · 2023Review
- Sustained-release losartan from peptide nanofibers promotes chondrogenesis.Frontiers in bioengineering and biotechnology · 2023Article
- Current understanding of osteoarthritis pathogenesis and relevant new approaches.Bone research · 2022Review
- The Mechanism and Role of ADAMTS Protein Family in Osteoarthritis.Biomolecules · 2022Review
- Losartan Alleviates the Side Effects and Maintains the Anticancer Activity of Axitinib.Molecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveLosartan and activation of the peroxisome proliferator-activated receptor-γ (PPARγ) have been previously reported to alleviate the progression of osteoarthritis (OA). However, the nature of the interaction between losartan and PPARγ in OA remains elusive. Therefore, we aimed to investigate the mechanism of the regulation of PPARγ by losartan in the context of OA.
methodsClinical samples of OA patients were collected and the chondrocytes were further isolated, and used to construct OA chondrocyte model via induction with IL-1β. An OA mouse model was developed by the surgical destabilization of the medial meniscus (DMM). OA chondrocytes were treated with losartan, PPARγ siRNA and the PPAR-
resultsThe downregulation of PPARγ and the upregulation of TGF-β1 signaling pathway were detected in the OA cartilage tissues and chondrocytes. Losartan treatment or PPARγ activation contributes to reduced levels of IL-6, IL-1β, TNF-α, and COX-2, expression of TGF-β1, MMP-13, ADAMTS-4, ADAMTS-5, HtrA1, and iNOS, along with reduced Smad2 and Smad3 phosphorylation, but elevated PPARγ and Collagen II expression
conclusionOur results show that losartan could arrest the progression of OA by upregulating PPARγ expression and inactivating the TGF-β1 signaling pathway.The translational potential of this article: Our results provide a biological rationale for the use of losartan as a potential candidate for OA treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.